• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Fight Over .Amazon: ACTO Countries Cancel Meeting With ICANN CEO

29/11/2018 by Monika Ermert for Intellectual Property Watch Leave a Comment

The fight over delegating the .amazon top-level domain to Amazon LLC is not over. But the effort of the Internet Corporation for Assigned Names and Numbers (ICANN) to cut a deal between the regional Amazon Cooperation Treaty Organisation (ACTO) and online retailer Amazon has failed, according to ICANN CEO Göran Marby. [updated]

Filed Under: IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Copyright Policy, English, ITU/ICANN, Information and Communications Technology/ Broadcasting, Latin America/Caribbean, North America, Regional Policy, Trademarks/Geographical Indications/Domains

ICANN Frees .Amazon Domain For Company Delegation

25/10/2018 by Monika Ermert for Intellectual Property Watch 1 Comment

The Internet Corporation for Assigned Names and Numbers (ICANN) has lifted the stop on delegating the .amazon top-level domain, effectively handing it to the company over the South American region, depending on agreement with states in the Amazon region.

Filed Under: IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, English, ITU/ICANN, Information and Communications Technology/ Broadcasting, Latin America/Caribbean, North America, Regional Policy, Trademarks/Geographical Indications/Domains

Research Group Identifies Over-Patenting Of Pharmaceuticals In India, Calls For Patent Reform

17/10/2018 by David Branigan, Intellectual Property Watch 2 Comments

The tricontinental research group “accessibsa” has found that while the Indian Patent Office rejects 40 percent of pharmaceutical patent applications, it should be rejecting 90 percent of applications to comply with Indian patent law, according to the results of its recent study of Indian patent data.

Filed Under: IP Policies, Language, Themes, Venues, Africa, Asia/Pacific, English, Health & IP, IP Law, Innovation/ R&D, Latin America/Caribbean, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer

Interview With Miguel Ángel Margáin, Director General Of The Mexican Institute Of Industrial Property

01/10/2018 by William New, Intellectual Property Watch Leave a Comment

Miguel Ángel Margáin, Director General of the Mexican Institute of Industrial Property, took office in early 2013, and was in Geneva for the annual World Intellectual Property Organization General Assemblies. William New of Intellectual Property Watch sat down with him for an interview. He spoke about achievements of the office during this administration, major amendments to adhere to global treaties and changes in the NAFTA, the introduction of geographical indications, and the ascendance of IP rights in Latin America.

Filed Under: Features, IP Policies, Language, Subscribers, Themes, Venues, English, Finance, Innovation/ R&D, Latin America/Caribbean, Patents/Designs/Trade Secrets, Regional Policy, Trademarks/Geographical Indications/Domains, Traditional and Indigenous Knowledge, WIPO

Interview With The President Of Brazil’s Industrial Property Institute

27/09/2018 by William New, Intellectual Property Watch 1 Comment

Luiz Otávio Pimentel is president of the National Institute of Industrial Property (INPI) of Brazil. In Geneva this week for the annual World Intellectual Property Organization General Assemblies he took time to sit down with Intellectual Property Watch’s William New. INPI is part of the Ministry of Industry, Foreign Trade and Services. On a breaking issue, Pimentel talked about the case in Brazil involving sofosbuvir, marketed as Sovaldi, Gilead’s effective medicine against hepatitis C that has been known for its exorbitant prices.

Filed Under: Features, IP Policies, Language, Themes, Venues, English, Health & IP, Human Rights, IP Law, Latin America/Caribbean, Patents/Designs/Trade Secrets, Regional Policy, WTO/TRIPS

Brazil Signs Deal With Medicines Patent Pool To Share Patent Information

25/09/2018 by Catherine Saez, Intellectual Property Watch 1 Comment

Brazil yesterday signed an agreement with the Medicines Patent Pool (MPP), through which the country will share patent information with the MPP. The Brazilian IP office joins several others in an effort to regular update of the MPP’s database on patent information. Separately, high-level representatives of Latin American and Iberian countries met on the side of the annual World Intellectual Property Organization General Assemblies taking place this week.

Filed Under: IP Policies, Language, Themes, Venues, English, Health & IP, Latin America/Caribbean, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer

Brazilian Supreme Court Refuses To Judge Its Biggest Case On IP And Access To Medicines, And Benefits Big Pharma With Undue Monopolies

13/09/2018 by Intellectual Property Watch 6 Comments

Marcela Fogaça Vieira and Pedro Villardi write: The Brazilian Supreme Court (STF) has mysteriously cancelled the judgment of the most important case regarding intellectual property and health ever to be decided by the court. On 28 June, the date of the judgment was set for 6 September. The cancellation occurred on the eve of the judgment, something very rare in the practice of the Court. The lack of decision on the case only benefits the transnational companies awarded with hundreds of undue monopolies. Just a few days before, the President of the STF – Judge Carmem Lucia – had a meeting with Interfarma, the association of multinational pharmaceutical companies in Brazil.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, Development, English, Health & IP, Human Rights, IP Law, Innovation/ R&D, Latin America/Caribbean, Patents/Designs/Trade Secrets, Regional Policy

New Health Ministry Of Chile Reaffirms Path To Compulsory Licence For Hepatitis C Drugs

04/09/2018 by Intellectual Property Watch Leave a Comment

Last week, Chilean Health Minister Emilio Santelices, appointed by President Piñera – who took office this year – rejected an attempt from company Gilead and a Big Pharma-related association of international drug makers in Chile to put down the resolution 399/2018 declaring public health justifications for the issuing of compulsory licences for sofosbuvir to treat a hepatitis C epidemic in Chile, that was issued by the previous government of Michele Bachelet, writes Luis Villarroel.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, Health & IP, Latin America/Caribbean, Patents/Designs/Trade Secrets, Regional Policy

O Paradoxo Das Patentes No Brasil E Suas Implicações Para O Acesso A Medicamentos

22/05/2018 by Intellectual Property Watch 2 Comments

O sistema de patentes foi supostamente projetado para permitir a recuperação do investimento em pesquisa e desenvolvimento (P&D) de um novo produto, através da venda sob exclusividade por um período de tempo. Vários estudos relacionaram preços altos de medicamentos à situação de monopólio estabelecida pelo sistema de patentes e outros direitos de monopólio (como a exclusividade de dados). É bastante estabelecido que a existência de uma patente pode levar a preços altos devido à condição de mercado em que um produtor pode operar com exclusividade. Vários estudos relacionaram preços elevados de medicamentos à situação de monopólio estabelecida pelo sistema de patentes e outros direitos de monopólio (como a exclusividade de dados). Na ausência de concorrência, um produtor pode cobrar praticamente qualquer preço pelo seu produto. A concorrência, portanto, pode promover uma redução significativa de preços e aumentar o acesso.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, Health & IP, Human Rights, Innovation/ R&D, Latin America/Caribbean, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer

Patent Backlogs Fuel Efforts To Extend Pharma Patent Terms In Thailand And Brazil, AIDS Activists Say

18/05/2018 by Dugie Standeford for Intellectual Property Watch 17 Comments

For a variety of reasons, Thailand and Brazil have huge backlogs of pharmaceutical patent applications. The delay in patent examinations is creating pressure on the countries to extend patent protection terms to the detriment of access to affordable medicines, AIDS organisations say.

Filed Under: IP Policies, Language, Themes, Venues, Asia/Pacific, Development, English, Finance, Health & IP, Health Policy Watch, Human Rights, Innovation/ R&D, Latin America/Caribbean, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Supported By, TRIPS Flexibilities, Technical Cooperation/ Technology Transfer, WTO/TRIPS

  • 1
  • 2
  • 3
  • …
  • 24
  • Next Page »
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting